327 related articles for article (PubMed ID: 16617300)
41. Fibroblast growth factor-2-retargeted adenoviral vector for selective transduction of primary glioblastoma multiforme endothelial cells.
Gupta V; Wang W; Sosnowski BA; Hofman FM; Chen TC
Neurosurg Focus; 2006 Apr; 20(4):E26. PubMed ID: 16709032
[TBL] [Abstract][Full Text] [Related]
42. Transcriptional targeting of tumors with a novel tumor-specific survivin promoter.
Zhu ZB; Makhija SK; Lu B; Wang M; Kaliberova L; Liu B; Rivera AA; Nettelbeck DM; Mahasreshti PJ; Leath CA; Barker S; Yamaoto M; Li F; Alvarez RD; Curiel DT
Cancer Gene Ther; 2004 Apr; 11(4):256-62. PubMed ID: 15017380
[TBL] [Abstract][Full Text] [Related]
43. Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis.
Li X; Jung C; Liu YH; Bae KH; Zhang YP; Zhang HJ; Vanderputten D; Jeng MH; Gardner TA; Kao C
J Gene Med; 2006 Jun; 8(6):679-89. PubMed ID: 16570242
[TBL] [Abstract][Full Text] [Related]
44. Combination of cytosine deaminase suicide gene expression with DR5 antibody treatment increases cancer cell cytotoxicity.
Kaliberov SA; Chiz S; Kaliberova LN; Krendelchtchikova V; Della Manna D; Zhou T; Buchsbaum DJ
Cancer Gene Ther; 2006 Feb; 13(2):203-14. PubMed ID: 16082379
[TBL] [Abstract][Full Text] [Related]
45. Tumour-specific therapeutic adenovirus vectors: repression of transgene expression in healthy cells by endogenous p53.
Lipinski KS; Djeha AH; Krausz E; Lane DP; Searle PF; Mountain A; Wrighton CJ
Gene Ther; 2001 Feb; 8(4):274-81. PubMed ID: 11313801
[TBL] [Abstract][Full Text] [Related]
46. Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model.
Lee YS; Kim JH; Choi KJ; Choi IK; Kim H; Cho S; Cho BC; Yun CO
Clin Cancer Res; 2006 Oct; 12(19):5859-68. PubMed ID: 17020994
[TBL] [Abstract][Full Text] [Related]
47. Gene therapy of adenovirus mediated CD ::upp/5-FC directed by GSTP1 promoter in cisplatin-resistant ovarian cancer.
Wang Z; Cai L; Wang H
Gynecol Oncol; 2005 Mar; 96(3):643-50. PubMed ID: 15721406
[TBL] [Abstract][Full Text] [Related]
48. [Adenovirus-mediated double suicide gene selectively kills breast cancer MCF-7 cells in vitro].
Kong H; Huang ZH; Li Q; Yang LC; Yu JL; Li Z
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Jun; 28(6):907-10. PubMed ID: 18583225
[TBL] [Abstract][Full Text] [Related]
49. [Construction of a RU486 inducible recombinant adenoviral vector carrying murine interleukin-12 gene and experimental treatment of colonic carcinoma].
Chen J; Liu XS; Wang F; Xue XC; Fang GE; Su CQ; Qian QJ
Zhonghua Yi Xue Za Zhi; 2009 May; 89(20):1372-6. PubMed ID: 19671324
[TBL] [Abstract][Full Text] [Related]
50. Targeting KRAS mutation-bearing lung cancer in vivo by pulmonary surfactant-adenovirus-mediated gene transfer.
Fukazawa T; Maeda Y; Matsuoka J; Ono T; Mominoki K; Yamatsuji T; Shigemitsu K; Morita I; Murakami I; Tanaka H; Durbin ML; Naomoto Y
Anticancer Res; 2010 Dec; 30(12):4925-35. PubMed ID: 21187472
[TBL] [Abstract][Full Text] [Related]
51. [The efficacy of autocatalytic casapse-3 driven by human telomerase reverse transcriptase promoter on human ovarian carcinoma].
Song Y; Shen K; Yu JR
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(41):2919-24. PubMed ID: 18261307
[TBL] [Abstract][Full Text] [Related]
52. Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control.
Simpson GR; Han Z; Liu B; Wang Y; Campbell G; Coffin RS
Cancer Res; 2006 May; 66(9):4835-42. PubMed ID: 16651439
[TBL] [Abstract][Full Text] [Related]
53. Dendritic cells modified to express fractalkine/CX3CL1 in the treatment of preexisting tumors.
Nukiwa M; Andarini S; Zaini J; Xin H; Kanehira M; Suzuki T; Fukuhara T; Mizuguchi H; Hayakawa T; Saijo Y; Nukiwa T; Kikuchi T
Eur J Immunol; 2006 Apr; 36(4):1019-27. PubMed ID: 16525992
[TBL] [Abstract][Full Text] [Related]
54. An oncolytic adenoviral vector carrying the tyrosinase promoter for glioma gene therapy.
Ulasov IV; Rivera AA; Nettelbeck DM; Rivera LB; Mathis JM; Sonabend AM; Tyler M; Wang M; Douglas JT; Lesniak MS
Int J Oncol; 2007 Nov; 31(5):1177-85. PubMed ID: 17912445
[TBL] [Abstract][Full Text] [Related]
55. Efficient and selective tumor cell lysis and induction of apoptosis in melanoma cells by a conditional replication-competent CD95L adenovirus.
Fecker LF; Schmude M; Jost S; Hossini AM; Picó AH; Wang X; Schwarz C; Fechner H; Eberle J
Exp Dermatol; 2010 Aug; 19(8):e56-66. PubMed ID: 19725869
[TBL] [Abstract][Full Text] [Related]
56. Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter.
Nettelbeck DM; Rivera AA; Balagué C; Alemany R; Curiel DT
Cancer Res; 2002 Aug; 62(16):4663-70. PubMed ID: 12183423
[TBL] [Abstract][Full Text] [Related]
57. Mode of transgene expression after fusion to early or late viral genes of a conditionally replicating adenovirus via an optimized internal ribosome entry site in vitro and in vivo.
Rivera AA; Wang M; Suzuki K; Uil TG; Krasnykh V; Curiel DT; Nettelbeck DM
Virology; 2004 Mar; 320(1):121-34. PubMed ID: 15003868
[TBL] [Abstract][Full Text] [Related]
58. A novel adenoviral vector which mediates hypoxia-inducible gene expression selectively in neurons.
Huang D; Desbois A; Hou ST
Gene Ther; 2005 Sep; 12(18):1369-76. PubMed ID: 15843806
[TBL] [Abstract][Full Text] [Related]
59. Insulated hsp70B' promoter: stringent heat-inducible activity in replication-deficient, but not replication-competent adenoviruses.
Rohmer S; Mainka A; Knippertz I; Hesse A; Nettelbeck DM
J Gene Med; 2008 Apr; 10(4):340-54. PubMed ID: 18265421
[TBL] [Abstract][Full Text] [Related]
60. MIA (melanoma inhibitory activity) promoter mediated tissue-specific suicide gene therapy of malignant melanoma.
Schoensiegel F; Paschen A; Sieger S; Eskerski H; Mier W; Rothfels H; Kleinschmidt J; Schadendorf D; Haberkorn U
Cancer Gene Ther; 2004 Jun; 11(6):408-18. PubMed ID: 15118759
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
